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T helper 17 (Th17) cells are important for host defense
against extracellular microorganisms. However, they
are also implicated in autoimmune and chronic
inflammatory diseases, and as such need to be
tightly regulated. The mechanisms that directly
control committed pathogenic Th17 cells in vivo
remain unclear. We showed here that IL-17A-
producing CD4+ T cells expressed interleukin-10
receptor a (IL-10Ra) in vivo. Importantly, T cell-
specific blockade of IL-10 signaling led to a selective
increase of IL-17A+IFN-g (Th17) and IL-17A+IFN-g+
(Th17+Th1) CD4+ T cells during intestinal inflamma-
tion in the small intestine. CD4+Foxp3 IL-10-pro-
ducing (Tr1) cells and CD4+Foxp3+ regulatory (Treg)
cells were able to control Th17 and Th17+Th1 cells
in an IL-10-dependent manner in vivo. Lastly, IL-10
treatment of mice with established colitis decreased
Th17 and Th17+Th1 cell frequencies via direct
signaling in T cells. Thus, IL-10 signaling directly
suppresses Th17 and Th17+Th1 cells.
INTRODUCTION
T helper 17 (Th17) cells, which are characterized by the produc-
tion of their signature cytokine IL-17A (Bettelli et al., 2007; Mios-
sec et al., 2009), are a T helper cell lineage distinct from Th1 and
Th2 cells. Th17 cells express the transcription factor RORgt,
which induces transcription of the Il17A gene (Annunziato et al.,
2009; Miossec et al., 2009). Th17 cells have been associated
with numerous autoimmune and chronic inflammatory diseases
(Miossec et al., 2009). In line with these associations, mice defi-554 Immunity 34, 554–565, April 22, 2011 ª2011 Elsevier Inc.cient in RORgt exhibit attenuated experimentally induced auto-
immune disease and lack tissue-infiltrating Th17 cells (Ivanov
et al., 2006). Moreover, adoptive transfer of in vitro differentiated
Th17 cells into lymphopenic hosts leads to the development of
colitis (Elson et al., 2007; Lee et al., 2009; Wang et al., 2009).
The cytokines responsible for the differentiation of Th17 cells are
already well defined; IL-6, TGF-b, and IL-1b are known to drive
Th17 cell differentiation (Bettelli et al., 2006; Mangan et al., 2006;
Sutton et al., 2006; Veldhoen et al., 2006). In addition, the cytokine
IL-23 maintains the expansion and pathogenicity of Th17 cells
(Ahern et al., 2010; McGeachy et al., 2009). Indeed, polymor-
phisms in the IL-23R gene have been linked with increased
susceptibility to inflammatory bowel disease (IBD) in humans
(Duerr et al., 2006). Furthermore, IL-23 is of major importance for
the induction of colitis inmousemodels. However, it is still unclear
whether the role of IL-23 is intrinsically restricted to the develop-
ment of pathogenic T cell populations. Of note also, Th1 cells are
unable to induce colitis in the absence of IL-23, which suggests
that IL-23might haveother, possibly T cell-extrinsic, effects (Ahern
et al., 2008). It was recently shown that IL-23 signaling is particu-
larly important for the emergence of IL-17A+IFN-g+CD4+ T cells,
which are referred to as ‘‘Th17+Th1’’ cells, in intestinal inflamma-
tion. This suggests that these double-producing cells play an
important pathogenic role in IBD (Ahern et al., 2010). Although
Th17 cells can be potentially pathogenic, this subset plays a key
role in the defense against external bacteria and fungi (reviewed
in Miossec et al., 2009). Therefore the mechanism that fine tunes
Th17 cells is obviously crucial but as yet is still poorly understood.
IL-10 has a nonredundant role in limiting inflammatory
responses in vivo, particularly in the intestine (Ku¨hn et al.,
1993). Mutations in the IL-10R are associated with IBD in
humans (Glocker et al., 2009). Mice deficient in IL-10 (Il10/)
or IL-10 receptor b (Il10rb/) are known to develop spontaneous
intestinal inflammation (Ku¨hn et al., 1993; Spencer et al., 1998).
However, IL-10 can act on a variety of immune cells: IL-10 acts
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Th17 Cells Are Controlled via IL-10directly on forkhead box P3 (Foxp3)+CD4+CD25+ regulatory T
(Treg) cells to maintain Foxp3 expression and suppressive
capacity (Murai et al., 2009), as well as on antigen-presenting
cells (Ding and Shevach, 1992; Fiorentino et al., 1991). Addition-
ally, several immune cells can produce IL-10. Among these are
the CD4+ regulatory T cells, out of which the two best-studied
subsets are Foxp3+ Treg cells and T regulatory type 1 (Tr1) cells
(Roncarolo and Battaglia, 2007).
Contradictory results have been published about the capacity
of Foxp3+ Treg cells to control Th17 cells. It is known that human
Foxp3+ Treg cell clones cannot suppress Th17 cell clones
(Annunziato et al., 2007). But it has been published recently
that the selective deletion of the transcription factor STAT3 in
murine Foxp3+ Treg cells leads to spontaneous intestinal inflam-
mation, which is associated with an increase in Th17 cells. These
data demonstrated indirectly that Foxp3+ Treg cells control Th17
cell response in a STAT3-dependent manner (Chaudhry et al.,
2009). However, the mechanism whereby Foxp3+ Treg cells
control Th17 cells was not identified in this study. A recent
work has shown that a selective reduction of induced Treg (iTreg)
cells in the gut-associated lymphoid tissue (GALT) unexpectedly
did not cause substantial immune-mediate lesion in the intestine
and, in addition, the frequencies of Th17 cells remained under
control (Zheng et al., 2010). This observation strongly suggests
that a compensatory mechanism is present in order to control
Th17 cells, at least in the GALT. Interestingly, the authors found
that Tr1 cells are strongly expanded in the absence of iTreg cells.
To summarize, it has been shown that IL-10 can control both
Th1 and Th17 cell immune responses (Ding and Shevach,
1992; Fiorentino et al., 1991; Fitzgerald et al., 2007; McGeachy
et al., 2007). It is also known that Tr1 and Foxp3+ Treg cells
can suppress T cell responses in vivo (Littman and Rudensky,
2010; Roncarolo and Battaglia, 2007). However, it is currently
unclear whether IL-10 acts directly on the different effector
T cells or mediates its inhibitory functions in an indirect manner
via antigen-presenting cells (APC). Likewise, the role of IL-10
signaling in effector T cells themselves for their suppression by
Tr1 and Foxp3+ Treg cells is unclear. Moreover, whether Tr1 cells
can compensate for a possible paucity of Foxp3+ Treg cells and
vice versa is currently considered an important unresolved point
in this field (Littman and Rudensky, 2010; Zheng et al., 2010).
Finally, despite the efficient control of Th17 cell differentiation
by IL-27, it is still unclear how mature Th17 cells can be
controlled (El-behi et al., 2009).
We found in two models of intestinal inflammation that IL-17A-
producingCD4+Tcells in contrast tonon-IL-17A-producingCD4+
T cells expressed high levels of IL-10Ra and that IL-10 signaling
in T cells controlled IL-17A+IFN-gCD4+ and IL-17A+IFN-g+
CD4+ T cells. Both Foxp3 IL-10-producing Tr1 cells and Foxp3+
Treg cells were independently able to suppress colitis caused
by the transfer of in vivo differentiated Th17 and Th17+Th1 cells
into lymphopenic hosts in an IL-10-dependent manner.
RESULTS
Differential Distribution of Pro- and Anti-inflammatory
T Helper Cells after Anti-CD3 Treatment
We previously reported that anti-CD3 treatment led to the
accumulation of IL-10-producing T cells in the small intestine(Kamanaka et al., 2006). It was also known that anti-CD3 treat-
ment led to a cytokine storm and systemic increased amounts
of TGF-b1 and IL-6 (Chatenoud and Bluestone, 2007). These
two cytokines induce the differentiation of Th17 cells (Bettelli
et al., 2006). Accordingly we found that anti-CD3 treatment
induced Th17 cells, which accumulated in the small intestine
(Figure 1 and unpublished data). Based on these data, we aimed
here to analyze whether IL-10 is important to control Th17 cells in
the small intestine after anti-CD3 treatment.
We found that the peak of IL-10 and IL-17A in the serum of
anti-CD3-treated mice occurred at the same time point, which
was at 52 hr after the first injection (Figure 1A). We next analyzed
the frequency of CD4+Foxp3IL-10+ T cells or CD4+Foxp3+
T cells (Foxp3+ Treg cells) by using the Foxp3 RFP and IL-10
eGFP double reporter mice (Kamanaka et al., 2006). The highest
frequency of CD4+Foxp3IL-10+ cells was found in the proximal
part of the small intestine (duodenum and jejunum), whereas the
frequency of Foxp3+ Treg cells was about the same in all parts of
the intestine (Figure 1B). We also analyzed the localization of
IL-17A+IFN-gFoxp3 and IL-17AIFN-g+Foxp3 producing
CD4+TCRab+ T cells. The highest frequency of IL-17A+IFN-g
Foxp3CD4+ T cells was in the small intestine, especially in
the duodenum and jejunum, whereas the frequency of IL-17A
IFN-g+Foxp3CD4+ T cells was again about the same in the
whole intestine (Figure 1B). Thus, IL-17A+CD4+TCRab+ and
Foxp3IL-10+CD4+TCRab+ T cells are induced in the same
time frame and are colocalized in the proximal part of the small
intestine after anti-CD3 treatment.
We next characterized the CD4+Foxp3IL-10+ T cells localized
in the proximal part of the small intestine. We found that about
30% of the IL-10-producing T cells also produced IFN-g and
only 6% produced IL-17A. In contrast, they did not produce IL-4
or TNF-a. Furthermore, they were able to suppress the prolifera-
tion of T cells in a dose-dependent manner in vitro. The suppres-
sive capacity of these cells could also be blocked by a combina-
tion of IL-10Ra, TGF-b1, and CTLA-4 antibodies (Figure 1C). In
contrast to IL-10 eGFP-negative T cells, the IL-10 eGFP-positive
cells expressed LAG-3 (Figure S1 available online), a marker
which has been recently associated with IL-10-producing CD4+
CD25Foxp3 regulatory T cells (Okamura et al., 2009).
Thus, these IL-10-producing CD4+ T cells fulfill all criteria
currently defining them as Tr1 cells (Gagliani et al., 2010; Groux
et al., 1997; Roncarolo and Battaglia, 2007), and our data show
that Th17 and Tr1 cells preferentially accumulated in the prox-
imal part of the small intestine after anti-CD3 treatment, whereas
Foxp3+ Treg cells, some of which also produce IL-10, were not
exclusively present in the small intestine.
IL-17A-Producing CD4+ T Cells Express IL-10Ra
CCR6, IL-23R, and IL-7R are known to be key receptors for
the differentiation of pathogenic Th17 cells, which are expressed
by the Th17 cell itself (Bettelli et al., 2007; Liu et al., 2010;
McGeachy et al., 2009). However, it is not known whether
Th17 cells express IL-10Ra. Because Tr1 and Th17 cells were
colocalized in the small intestine, we investigated whether
Th17 cells express IL-10Ra and could therefore respond to
IL-10. By using IL-17A eGFP reporter mice, we could verify
IL-10R expression on freshly isolated IL-17A eGFP+ cells without
the need to restimulate the cells in vitro. This was important,Immunity 34, 554–565, April 22, 2011 ª2011 Elsevier Inc. 555
Figure 1. Colocalization of Tr1 and Th17
Cells in the Small Intestine after CD3-
Specific Antibody Treatment
Foxp3 RFP IL-10 eGFP double reporter mice were
injected i.p. with anti-CD3 at 0 and 48 hr (see
arrows in A).
(A) Serum concentrations of IL-17A and IL-10
(mean ± SEM).
(B) Cells were isolated from different organs as
indicated. Foxp3 RFP and IL-10 eGFP expression
was measured in freshly isolated cells. IL-17A and
IFN-g expression was measured in restimulated
cells via intracellular cytokine staining (ICS). Cells
are gated on CD4+TCRb+. Numbers in quadrants
indicate percentage of cells.
(C) CD4+TCRb+Foxp3 RFP IL-10 eGFP+
(CD45.2+) cells were isolated from the small
intestine after anti-CD3 treatment. ICS was per-
formed for IL-17A, IFN-g, IL-4, and TNF-a (top).
The suppressive capacity was measured by
CFSE dilution of CD45.1+ responder cells. TGF-b,
IL-10Ra, and CTLA-4 antibodies were added as
indicated (bottom). Numbers in quadrants indicate
percentage of cells.
Results are representative of at least three inde-
pendent experiments.
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Naive T cells showed a very low expression of IL-10Ra (Fig-
ure 2A). In contrast, in vivo differentiated IL-17A eGFP+CD4+
T cells, which accumulated in the proximal part of the small intes-
tine after anti-CD3 treatment, expressed IL-10Ra (Figure 2B, red
line). In line with this observation, IL-17A eGFP+CD4+ T cells
in the CD45RBhi transfer colitis model also expressed IL-10Ra
(Figure 2C, red line). In contrast, IL-17A eGFPCD4+ T cells ex-
pressed lower amounts of IL-10Ra (Figures 2B and 2C, blue line).
Thus, in vivo differentiated IL-17A-producing CD4+ T cells
express IL-10Ra and are therefore in principle able to respond
to IL-10.
IL-10 Signaling in T Cells Controls the Emergence
of IL-17A+IFN-g–CD4+ and IL-17A+IFN-g+CD4+ T Cells
It is known that Il10/mice develop more severe tissue damage
in the small intestine after anti-CD3 treatment compared to wild-
type (WT) mice (Zhou et al., 2004), suggesting an important regu-
latory role of IL-10 in this model. However, the cellular target of
IL-10 was not identified in this study, and the effect of IL-10 defi-
ciency on different T cell subsets was also not addressed.
In order to study the role of IL-10 signaling, specifically in
T cells, we previously generated transgenic (Tg) mice, in which
IL-10 signaling is specifically blocked in T cells by the overex-556 Immunity 34, 554–565, April 22, 2011 ª2011 Elsevier Inc.pression of a dominant-negative IL-
10Ra under the Cd4 promoter (Cd4-
DNIL-10R). Of note, these mice had no
spontaneous immune phenotype (Fig-
ure S2) and also did not spontaneously
develop IBD (Kamanaka et al., 2011).
We therefore used the Cd4-DNIL-10R
transgenic mice to analyze the role of
IL-10 signaling in T cells in this model.Both WT and Cd4-DNIL-10R transgenic mice rapidly lost weight
after anti-CD3 treatment. However, 100% of the WTmice recov-
ered after the treatment and started to gain weight 72 hr after the
first injection. In contrast, the Cd4-DNIL-10R transgenic mice
continued to lose weight and 45% of the transgenic mice died
about 72 hr after the first injection (Figure 3A). In line with the
increased mortality, Cd4-DNIL-10R transgenic mice had higher
IL-17A, IFN-g, and TNF-a serum concentrations 52 hr after
anti-CD3 treatment compared to WT mice (Figure 3B). Based
on intracellular cytokine staining, we compared the frequency
of IL-17A-, IFN-g-, and TNF-a-producing CD4+TCRb+ T cells in
the small intestine 52 hr after CD3-specific antibody treatment
in WT and Cd4-DNIL-10R transgenic mice. The frequency of
IL-17A+IFN-gCD4+ T cells was significantly increased in Cd4-
DNIL-10R transgenic mice compared to WT mice, whereas the
frequency of IL-17AIFN-g+ cells was equal between Cd4-
DNIL-10R transgenic and WT mice (Figures 3C and 3D). The
increased IFN-g and TNF-a serum concentrations in Cd4-
DNIL-10R transgenic mice correlated with increased fre-
quencies of IL-17A+IFN-g+ and also IL-17A+TNF-a+ double-
producing CD4+ T cells compared to WT mice (Figures 3C and
3D). We also found increase in TNF-a+IL-17ACD4+ T cells in
some Cd4-DNIL-10R transgenic compared to WT mice (Fig-
ure 3C). This difference was nevertheless not statistically
Figure 2. IL-10Ra Is Highly Expressed on IL-17A-Producing CD4+
T Cells
IL-10Ra expression was measured by flow cytometry.
(A) Cells are gated on naive T cells (CD45.2+CD4+TCRb+Foxp3CD44
CD62Lhi) isolated from the spleen and lymph nodes of untreated Foxp3 RFP
IL-17A eGFP reporter mice.
(B) Cells are gated on CD4+TCRb+CD44hi cells from the small intestine after
anti-CD3 treatment.
(C) CD4+CD45.2+Foxp3–CD45RBhi cells were isolated from the spleen of
Foxp3-RFP IL-17A-eGFP double reporter mice and injected i.p. into CD45.1+
Rag1/ mice. Cells are gated on CD4+CD45.2+CD44hi IL-17A eGFP+ cells
isolated from the mLN 3 weeks after the transfer.
Grey area represents the isotype control. Results are representative of at least
two independent experiments.
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Of note, the total CD4+TCRb+ cell numbers in the small intestine
were not different at this time point (WT, 262 ± 18.3 versus Tg,
313 ± 28.6 [3103]; p = 0.4). Therefore, the total cell numbers of
IL-17A+IFN-gCD4+ T cells (WT versus Tg, 43.7 ± 5.5 versus
77.9 ± 13.2 [3103]; p < 0.02) and IL-17A+IFN-g+CD4+ T cells
(WT versus Tg, 12.4 ± 2 versus 26.4 ± 2.8 [3103]; p < 0.02) but
not IL-17AIFN-g+CD4+ T cells were different (WT versus Tg,
39.5 ± 5.4 versus 47.4 ± 5.9 [3103]; p = 0.31). In conclusion,
T cell-specific blockade of IL-10 signaling led to increased
frequencies and numbers of IL-17A+IFN-gCD4+ and IL-17A+
IFN-g+CD4+, but not IL-17AIFN-g+CD4+, T cells in the small
intestine after anti-CD3 treatment.
IL-10 Signaling in T Cells Inhibits the Proliferation
of IL-17A-Producing CD4+ T Cells
Because we found increased number of IL-17A-producing
T cells in the small intestine of Cd4-DNIL-10R transgenic mice
after anti-CD3 treatment, we next analyzed whether IL-10controls the proliferation of IL-17A-producing T cells. We found
that IL-17A eGFP+ transgenic T cells with blocked IL-10 signaling
proliferated more in vivo based on BrdU uptake compared toWT
(Figure 4A). Consequently, the numbers of IL-17A eGFP+CD4+
T cells increased in Cd4-DNIL-10R transgenic mice over time
but not in WT mice (Figure 4B). It is important to mention that
the frequency of Tr1 and Foxp3+ Treg cells, which are known
to be induced or expanded by anti-CD3 treatment, was not
different between WT and Cd4-DNIL-10R transgenic mice (Fig-
ure 4B). However, although the frequency and numbers of Tr1
and Foxp3+ Treg cells were not affected, our data do not exclude
a possible effect of IL-10 on the functionality of Tr1 and Foxp3+
Treg cells. As shown in Figure 1C, there were also some IL-17A+
IL-10+ double-producing T cells in the small intestine. Although
the fraction of IL-17A-producing cells within the IL-10-producing
cell population was relatively small, this fraction represented up
to 30% of all IL-17A-producing T cells. However, we also could
not find a significant difference between WT and Cd4-DNIL-10R
mice in the emergence of IL-17A+IL-10+ double-producing CD4+
T cells after anti-CD3 treatment (Figure S3).
Thus, T cell-specific blockade of IL-10 signaling led preferen-
tially to the expansion of IL-17A+IFN-g and IL-17A+IFN-g+, but
not IL-17AIFN-g+, CD4+ T cell numbers. Additionally, the
frequency of IL-17A+TNF-a+CD4+ T cells was also increased in
Cd4-DNIL-10R transgenic mice compared to WT. Moreover,
the increased number of these T cells was associated with in-
creasedmortality inCd4-DNIL-10R transgenicmice. By contrast,
the frequency of IL-10-producing T cells was not different
between WT and Cd4-DNIL-10R mice, indicating that IL-10
signaling inTcells isdispensable for theemergenceof thesecells,
which is in line with a previous study (Maynard et al., 2007).
Tr1 Cells Inhibit Colitis Induced by IL-17A+IFN-g–CD4+
and IL-17A+IFN-g+CD4+ T Cells via IL-10
We next hypothesized that IL-10-producing regulatory T cells,
such as Tr1 cells, can suppress Th17 cell-mediated disease
via IL-10.
We found that after anti-CD3 treatment of WT mice, about
30% of the IL-17A+CD4+ T cells produced IL-10, only few
secreted TNF-a, and only 20% produced IFN-g (Figure 3; Fig-
ure S3). In line with this less pathogenic phenotype, anti-CD3
treatment of WT caused only transient pathology in the small
intestine. In contrast, 50% of the IL-17A-producing CD4+
T cells in the CD45RBhi T cell transfer colitis model produced
IFN-g. Moreover, most of them also secreted TNF-a (Figure S4).
Of note, the IL-17A-producing T cells in the transfer colitis model
have a more similar phenotype to the Cd4-DNIL-10R transgenic
IL-17A-producing T cells in the CD3 model (Figure 3; Figure S4).
We therefore aimed to test whether Tr1 and Foxp3+ Treg cells
could inhibit Th17 cells with a more pathogenic phenotype,
which are present in the CD45RBhi T cell transfer colitis model.
To that end we transferred CD4+CD45RBhi T cells isolated
from the IL-17A eGFP Foxp3 RFP double-reporter mice into
Rag1/ mice, and once the recipient mice developed intestinal
inflammation, we isolated CD4+IL-17A+Foxp3 T cells from the
inflamed colon and mesenteric lymph nodes. These CD4+IL-
17A eGFP+ T cells included IL-17A+TNFa+, IL-17A+IFN-g, and
IL-17A+IFN-g+ cells (Figure S4). Importantly, all CD4+ IL-17A
eGFP+ T cells in the CD45RBhi transfer colitis model expressedImmunity 34, 554–565, April 22, 2011 ª2011 Elsevier Inc. 557
Figure 3. T Cell-Specific Blockade of IL-10
Signaling Leads to Increased Mortality after
Anti-CD3 Treatment
Cd4-DNIL-10R (Tg) or WT mice were injected with
anti-CD3.
(A) Mass loss (mean ± SEM; WT, n = 8; Tg, n = 10)
and mortality (cumulative from three experiments)
are shown.
(B–D) Mice were analyzed 52 hr after the first
injection.
(B) IL-17A, IFN-g, and TNF-a serum concentra-
tions (mean ± SEM; WT, n = 7; Tg, n = 4).
(C) Cells were isolated from the small intestine and
IL-17A, IFN-g, and TNF-a expression analyzed by
ICS. Numbers in quadrants indicate percentage of
cells.
(D) Statistical overview of different T cell subsets
in the small intestine after anti-CD3 injection as
determined by ICS. Each dot represents one
mouse. Lines indicate mean. Cells were gated on
CD4+TCRb+ events.
Results are representative of at least three inde-
pendent experiments.
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into Rag1/mice without any further in vitro expansion or stim-
ulation. Transfer of these in vivo differentiated pathogenic IL-
17A-producing CD4+ T cells caused disease in the colon of the
recipients, based on weight loss and histological and endo-
scopic findings (Figures 5A–5E). In contrast, the development
of intestinal disease was blocked by cotransferring Tr1 cells, iso-
lated from the small intestine of anti-CD3-treated mice (Figures
5A–5E). The complete suppression of the disease was depen-
dent on IL-10 signaling in the effector T cells, because Tr1 cells
were not able to suppress disease mediated by the transfer of
in vivo differentiated Cd4-DNIL-10R transgenic effector cells
(Figures 5A–5E). Tr1 cells alone did not cause disease (Figure 5),
although some of these cells produced IFN-g (Figure 1C).
Of note, the transfer of WT and Cd4-DNIL-10R transgenic
IL-17A+CD4+ effector T cells caused disease to about the
same severity. This indicated that the IL-10 amounts in the558 Immunity 34, 554–565, April 22, 2011 ª2011 Elsevier Inc.Rag1/ host were not able to inhibit
development of disease caused by either
WT or Cd4-DNIL-10R transgenic IL-17A+
effector T cells.
Thus, through their IL-10 production,
Tr1 cells could suppress colitis induced
by the transfer of IL-17A+IFN-gCD4+
and IL-17A+IFN-g+CD4+ T cells.
Foxp3+ Treg Cells Suppress Colitis
Induced by
IL-17A+IFN-g– and IL-17A+IFN-g+
CD4+ T Cells via IL-10
Foxp3+ Treg cells have evolved several
mechanisms to suppress effector
T cells. But it is still not known whether
Foxp3+ Treg cells can directly control
Th17 cells in vivo and, if they do, which
mechanism they are using. Analogous tothe approach we used to analyze the in vivo suppressive
capacity of Tr1 cells, we cotransferred in vivo generated
IL-17A+IFN-gCD4+ and IL-17A+IFN-g+CD4+ T cells, isolated
from the colon and mesenteric lymph nodes of mice with estab-
lished colitis, with Foxp3+ Treg cell isolated from the spleen of
anti-CD3-treated mice, into Rag1/ mice. The Foxp3+ Treg
cells were isolated from the spleen, because it was not possible
to isolate sufficient numbers of these cells from the small intes-
tine of anti-CD3-treated mice. Foxp3+ Treg cells were able to
suppress diseasemediated by the transfer of these effector cells
to a similar degree as the Tr1 cells. In contrast, Foxp3+ Treg cells,
isolated from Foxp3-cre-YFP-Il10flox/flox mice (Rubtsov et al.,
2008), were not able to suppress disease development, suggest-
ing an essential role of Foxp3+ Treg cell-derived IL-10 for this
suppression (Figures 6A–6E). We next cotransferred WT
Foxp3+ Treg cells with Cd4-DNIL-10R transgenic IL-17A
eGFP+ T cells. Here we did not find a significant suppressive
Figure 4. IL-10 Signaling in T Cells Inhibits
the Proliferation of IL-17A-Producing
T Cells
(A) BrdU uptake was measured in CD4+TCRb+IL-
17A eGFP+ cells isolated from WT and Cd4-DNIL-
10R mice (left). BrdU was injected 12 hr before
mice were sacrificed. Time course experiment of
total numbers of CD4+TCRb+IL-17A+ cells after
CD3-specific antibody treatment (mean ± SEM;
WT: 0 hr, n = 4; 48 hr, n = 2; 52 hr, n = 5; 96 hr, n = 5;
Tg: 0 hr, n = 4; 48 hr, n = 2; 52 hr, n = 4; 96 hr, n = 5)
(right). Left: Mice were analyzed 52 hr after the first
anti-CD3 injection. Data are representative of
three independent experiments. Right: Data are
cumulative from three independent experiments.
(B) Foxp3 RFP and IL-10 eGFP expression was
measured in freshly isolated cells. Cells are gated
on CD4+TCRb+ events. Mice were analyzed 52 hr
after the first anti-CD3 injection. Data are cumu-
lative from three independent experiments.
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T cell-mediated disease based on mass loss, endoscopic, and
histological colitis score (Figures 6A–6E).
These data indicate that Foxp3+ Treg cell-derived IL-10 is
essential for the suppression of disease mediated by the transfer
of IL-17A+IFN-gCD4+ and IL-17A+IFN-g+CD4+ T cells and that
the IL-10 produced by the Rag1/ host is not able to compen-
sate for this T cell-derived IL-10. Furthermore, the suppression is
dependent on IL-10 signaling in the transferred effector IL-17A+
T cells.
IL-10 Suppresses IL-17A+IFN-g–CD4+ and
IL-17A+IFN-g+CD4+TCells inMicewithEstablishedColitis
Through production of IL-10, both Tr1 cells and Foxp3+ Treg
cells were able to suppress disease mediated by the transfer
of in vivo differentiated IL-17A+IFN-gCD4+ and IL-17A+IFN-g+
CD4+ T cells. Unfortunately, in the previous transfer model we
could not address which T cell subset (IL-17A+IFN-g or
IL-17A+IFN-g+) was affected by the cotransferred regulatory
T cells. The reason was the limited number of cells that could
be used for these transfer experiments and consequently recov-
ered from the protected mice. To overcome this problem, we
took advantage of the CD45RBhi T cell transfer colitis model,
the same model that we used to isolate IL-17A eGFP+ T cells
for the previous described transfer experiments. CD4+Foxp3
CD45RBhi T cells from Foxp3 RFP reporter mice were trans-
ferred into Rag1/ mice. As mentioned before, IL-17A eGFP+
cells expressed high IL-10Ra (Figure 2C). As shown in Figure S4,
IFN-g+IL-17A, IL-17A+IFN-g, and IL-17A+IFN-g+ T cells were
present in the Rag1/ host 4 weeks after the transfer of CD4+
Foxp3CD45RBhi cells. In order to analyze the effect of IL-10Immunity 34, 554–5on these different T cell subsets, we
treated the Rag1/ mice at this time
point with recombinant IL-10. IL-10-
treated mice demonstrated a reduced
frequency of IL-17A+IFN-g and IL-17A+
IFN-g+ T cells compared to untreated
animals in the mesenteric lymph nodesand colon (Figure 7, data not shown). In this colitis model, almost
all IL-17A+ T cells were also TNF-a+. Accordingly, the frequency
of IL-17A+TNF-a+ T cells was also reduced in IL-10-treated mice
compared to untreated controls (Figure 7). In contrast, the
frequency of IL-17AIFN-g+ and TNF-a+IL-17A– T cells was not
different between IL-10-treated and untreated animals. In order
to test whether IL-10 signaling in T cells was involved in the
reduced frequency of IL-17A+IFN-g and IL-17A+IFN-g+
T cells, we repeated the experiment mentioned above with
Cd4-DNIL-10R transgenic CD4+Foxp3CD45RBhi. If CD4+
Foxp3CD45RBhi with impaired IL-10 signaling were trans-
ferred, we could not find any significant change in the frequency
of any of these T cells subsets, indicating that the reduction of
IL-17A+IFN-g and IL-17A+IFN-g+ T cell frequencies were
dependent on IL-10 signaling in T cells (Figure 7).
In conclusion, these data show that IL-10 signaling in T cells
preferentially controls the emergence of both IL-17A+IFN-g
and IL-17A+IFN-g+ T cells. This is in line with IL-10Ra expression,
which is high in IL-17A-producing cells but low in non-IL-17A-
producing T cells (Figure 2). However, although the frequency
of IFN-g+IL-17A T cells was not affected, our data do not
exclude a possible effect of IL-10 on the functionality of Th1 cells.
DISCUSSION
Mechanisms that can control directly previously committed
pathogenic Th17 cells are still not well understood. In this study
we tested whether Tr1 and Foxp3+ Treg cells are able to control
Th17 cells, and if they do, which mechanism they use. We found
that all IL-17A-producing T cells, which include IL-17A+IFN-g
and IL-17A+IFN-g+ T cells, expressed IL-10Ra. In line with this65, April 22, 2011 ª2011 Elsevier Inc. 559
Figure 5. Tr1 Cells Suppress Disease Mediated by Transfer of In Vivo Differentiated IL-17A+IFN-g–CD4+ and IL-17A+IFN-g+CD4+ T cells into
Rag1–/– Mice via IL-10
IL-17A-producing T cells were isolated from the colon andmLN as described in Figure S4. Tr1 cells were isolated from the small intestine of anti-CD3-treatedmice
and injected i.p. alone or together with IL-17A+ eGFP+ (IL-17A+) cells (WT or Cd4-DNIL-10R [Tg]) into Rag1/ mice.
(A–C) Mass loss (A), endoscopic (B), and histological (C) colitis score were measured. Each dot represents one mouse. Lines indicate mean.
(D) Representative endoscopic findings are shown. Note the bleeding (arrowhead), loss of translucency, stool inconsistency (*), fibrin (**), and increased mucosal
granularity (#) in the mice receiving IL-17A+ (WT), IL-17A+ (Tg) + Tr1, and IL-17A+ (Tg) cells.
(E) Representative HE sections of colon are shown. The overall morphology in the colon of mice receiving IL-17A+ (WT)+Tr1 and Tr1 cells was not different from
controls. Colons frommice receiving IL-17A+ (WT), IL-17A+ (Tg) + Tr1, and IL-17A+ (Tg) cells all had significant inflammation (*), crypt loss (arrowhead), edema (**),
and moderate to marked mucosal hyperplasia (double arrows). HE scale bars represent 1000 mm.
Results are cumulative from three independent experiments.
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Figure 6. Treg Cells Suppress Disease Mediated by Transfer of In Vivo Differentiated IL-17A+IFN-g–CD4+ and IL-17A+IFN-g+CD4+ T Cells into
Rag1–/– Mice via IL-10
IL-17A-producing T cells were isolated from the colon and mLN as described in Figure S4. CD4+TCRb+Foxp3 YFP+ (Treg cells) were isolated from the spleen of
Foxp3-cre-YFP-Il10flox/flox (Treg Il10/) or Foxp3-cre-YFP-Il10flox/wt (Treg WT) control mice after anti-CD3 treatment. Treg cells were injected i.p. into Rag1/
mice alone or together with IL-17A+ eGPF+ (IL-17A+) T cells (WT or Cd4-DNIL-10R [Tg]).
(A–C) Mass loss (A), endoscopic (B), and histological (C) colitis score were measured. Each dot represents one mouse. Lines indicate mean.
(D) Representative endoscopic findings are shown. Note the bleeding (arrowhead), loss of translucency, stool inconsistency (*), fibrin (**), and increased mucosal
granularity (#).
(E) Representative HE sections of colon. The overall morphology of the colon from mice receiving IL-17A+ (WT) + Treg (WT) cells was not different from controls
(see Figure 5E). Colons frommice receiving IL-17A+ (WT), IL-17A+ (WT)+Treg (Il10/), IL-17A+ (Tg), and IL-17A+ (Tg)+Treg cells all had significant inflammation (*),
variable crypt loss (arrowheads), edema (**), andmoderate tomarkedmucosal hyperplasia (M). Luminal floodingwith neutrophils was observed in somemicewith
server colitis (arrow). Scale bars represent 500 mm. Results are representative of three independent experiments withWT Treg cells and twowith Foxp3-cre-YFP-
Il10flox/flox Treg cells.
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Figure 7. IL-10 Inhibits IL-17A+IFN-g– and IL-17A+IFN-g+CD4+ T Cells in the T Cell Transfer Colitis Model
CD4+CD45.2+Foxp3CD45RBhi cells (WT and Cd4-DNIL-10R transgenic) were injected i.p. into CD45.1+Rag1/mice. Three to four weeks later, Rag1/mice
were injected three times on every other day with IL-10 (75 ng/mouse) or PBS i.v. Cells were isolated from the mLN, and ICS for IL-17A, IFN-g, and TNF-a was
performed (top). Cells were gated on CD4+CD45.2+ events. Numbers in quadrants indicate percentage of cells. Bottom: Each dot represents one mouse. Lines
indicate mean. Results are cumulative from three independent experiments.
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Th17 Cells Are Controlled via IL-10observation, IL-10 produced by Tr1 or Foxp3+ Treg cells
controlled mature Th17 and Th17+Th1 cells, but not Th1 cells,
in a direct manner.
Prior studies have shown that IL-10 can inhibit Th17 cell
immune responses in vivo. However, these studies are based
on the use of neutralizing IL-10 mAb or IL-10-deficient T cells
(Fitzgerald et al., 2007; McGeachy et al., 2007). It is therefore
not clear whether IL-10 acts directly on Th17 cells or exerts its
suppressive function indirectly, for example via APCs. Also,
whether IL-10 signaling in Th17 cells themselves is important
for their suppression by Foxp3+ Treg and Tr1 cells is unknown.
We recently found that IL-10 signaling in T cells is particularly
important to control the CD4+Foxp3CD45RBlo T cell pool
upon transfer into a lymphopenic host (Kamanaka et al., 2011).
However, from this study, it is still not clear whether IL-10 can
directly control Th17 or Th1 cells. Of note two in vitro studies aim-
ing to analyze the role of IL-10 on Th1 and Th17 cells (Gu et al.,562 Immunity 34, 554–565, April 22, 2011 ª2011 Elsevier Inc.2008; Naundorf et al., 2009) apparently contradict each other.
The in vitro study by Naundorf et al. (2009), who used human
PBMCs, suggested that IL-10might directly inhibit TCR-induced
IFN-g but not IL-17A production. In contrast, Gu et al. (2008)
found that IL-10 inhibits IL-17A production in T cells in vitro in
a total mouse splenocyte culture and that APCs contribute to
the negative regulation of Th17 cell differentiation by IL-10.
Th17 cells are defined as IL-17A-producing CD4+TCRab+
T cells. However, further complexity may derive from the exis-
tence of IL-17A+IFN-g+ double-producing T cells, which are
referred to as ‘‘Th17+Th1’’ cells (Annunziato et al., 2009).
Th17+Th1 cells have been described in patients with Crohn’s
disease (Annunziato et al., 2007), and it has been suggested
that they play amajor role in the development of intestinal inflam-
mation inmurine colitis models (Ahern et al., 2010).We found that
IL-10 signaling in T cells controls Th17 and Th17+Th1 cells, but
not Th1 cells, in vivo and the main source of IL-10 in our
Immunity
Th17 Cells Are Controlled via IL-10experiments appears to be Tr1 and Foxp3+ Treg cells. However,
our data do not exclude a possible further contribution of
APC-derived IL-10 for the suppression of Th17 cells in vivo.
Several publications during the last years have suggested that
a balance between effector T cells, such as Th1 and Th17 cells,
and different types of regulatory T cells, such as Tr1 and Foxp3+
Treg cells, is essential in order to maintain immune homeostasis,
especially in the intestine (reviewed in Littman and Rudensky,
2010). It was, however, not clear whether Tr1 or Foxp3+ Treg
cells can directly inhibit Th17 cells in vivo. An additional point
is that most studies of Th17 and also Tr1 cells were based on
the use of in vitro differentiated Th17 (Elson et al., 2007; Lee
et al., 2009; Wang et al., 2009) or Tr1 (Groux et al., 1997) cells,
respectively. Here we used reporter mice to purify in vivo differ-
entiated Tr1, Foxp3+ Treg, and Th17 cells to address these ques-
tions. IL-17A+-producing CD4+ T cells, comprising Th17 and
Th17+Th1 cells, isolated from the CD45RBhi T cell transfer colitis
model caused disease in the colon upon transfer into another
lymphopenic host. Both Tr1 and Foxp3+ Treg cells were inde-
pendently capable of inhibiting this disease, and this suppres-
sion was dependent on IL-10 signaling in the effector T cells.
By using this model, however, it was not possible to analyze
whether IL-10 inhibits IL-17A+IFN-g and IL-17A+IFN-g+ T cells
individually or both. Another possibility would be that IL-10 acted
on the effector T cells after they converted into IL-17AIFN-g+
T cells. To address this question, we used the CD4+CD45RBhi
T cell transfer colitis model, in which IL-17A+IFN-g, IL-17A+
IFN-g+, and IL-17AIFN-g+ T cells are present (Ahern et al.,
2010). We found that treatment with IL-10 in this T cell transfer
colitis model led to a selective reduction of IL-17A+IFN-g and
IL-17A+IFN-g+, but not IL-17AIFN-g+ T cells. Furthermore, the
effect was dependent on IL-10 signaling in T cells. This result
was in line with our data obtained with the model of anti-CD3
treatment in which also the frequency of IL-17A+IFN-g and
IL-17A+IFN-g+, but not IL-17AIFN-g+, T cells was significantly
changed by the blockade of IL-10 signaling. Thus, our results
demonstrated that IL-10 acts preferentially on IL-17A+IFN-g
(Th17) and IL-17A+IFN-g+ (Th17+Th1) cells rather than on
IL-17AIFN-g+ (Th1) cells. These data seem to be in contrast
with previous publications, which described an inhibitory role
of IL-10 on Th1 cells (Berg et al., 1996; Fiorentino et al., 1991).
However, the reduction of the Th1 cell response by IL-10 was
shown to be indirect and instead mediated by inhibition of APC
(Darrah et al., 2010; Ding and Shevach, 1992; Fiorentino et al.,
1991). Additionally, the role of IL-10 on IL-17A+IFN-g+
(Th17+Th1) double-producing CD4+ T cells was not analyzed
in these studies. We found that IL-10 signaling in T cells inhibited
the emergence of these double-producing T cells but not IFN-g
single-producing T cells in a direct manner.
IL-27 can inhibit the differentiation of Th17 cells, but it has little
direct influence on already committed Th17 cells (El-behi et al.,
2009; Fitzgerald et al., 2007; Stumhofer et al., 2006, 2007). It
was therefore still an open question which cytokine directly
controls committed pathogenic Th17 cells. Of note, our study
provides evidence that IL-10 controls Th17 and Th17+Th1 cells
in a direct manner in vivo. Taken together, IL-27 can inhibit the
differentiation of Th17 cells, whereas IL-10, which can also be
induced by IL-27 (Fitzgerald et al., 2007), controls committed
Th17 cells in a direct manner.It is currently still unclear which factors drive the pathogenicity
of Th17 cells. Others and we have shown that IL-22 and IL-17A,
both cytokines produced by Th17 cells, have a protective func-
tion in colitis (O’Connor et al., 2009; Ogawa et al., 2004;
Zenewicz et al., 2008). The CD45RBhi T cell transfer colitis is typi-
cally characterized by ulceration of the mucosa. Interestingly,
transfer of IL-17A-deficient T cells is associated with increased
ulceration of the mucosa in the colon (O’Connor et al., 2009).
We found here that transfer of in vivo differentiated IL-17A+-
producing CD4+ T cells (including IL-17A+IFN-g and IL-17A+
IFN-g+ T cells) into Rag1/ mice caused colitis, which was
characterized by inflammation, edema, crypt loss, and hyper-
plasia. However, ulceration was not characteristically seen in
our studies, with only 40% of Rag1/ mice that were injected
with in vivo differentiated Th17 and Th17+Th1 cells demon-
strating even mild ulceration of the mucosa (7 out of 18 mice).
Taken together, the data presented here are consistent with
the notion that although Th17 cells are proinflammatory,
selected Th17 cell-associated molecules, including IL-17A,
IL-22, and possibly others, might also have tissue-protective
properties (O’Connor et al., 2009; Zenewicz et al., 2008).
It should be mentioned that CD3-specific antibody is already
used as a therapy in human disease studies, most successfully
for type 1 diabetes, although the mechanisms of CD3-specific
antibody-induced tolerance is only still partially understood (Cha-
tenoud and Bluestone, 2007). We found that this treatment, at
least in a mouse model, also induced Th17 cells. However, we
also found, in line with previous in vitro findings (McGeachy
et al., 2007), that these Th17 cells can produce IL-10 in vivo. We
extended this finding and showed that Th17 cells also expressed
IL-10Ra and could therefore in principle be regulated by autocrine
IL-10 production. However, it seems that pathogenic Th17 cells,
which can be found for example in EAE or IBD, do not produce
IL-10 and therefore need to be controlled by regulatory T cells.
In conclusion, our data show that both Tr1 and Foxp3+ Treg
cells are able to inhibit mature and pathogenic Th17 and
Th17+Th1 cells independently via IL-10, suggesting that Tr1 cells
can compensate for a possible paucity of Foxp3+ Treg cell, and
vice versa. Moreover, IL-10 can act directly on the T cells to
inhibit Th17 and Th17+Th1 cells. The overlapping protective
function of Foxp3+ Treg and Tr1 cells is likely to be of selective
benefit to the host when confronted with an inflammatory insult
at its mucosa.
EXPERIMENTAL PROCEDURES
Mice
C57BL/6 mice (B6), C57BL/6 Rag1/mice, and C57BL/6 CD45.1+ mice were
purchased from The Jackson Laboratories. Foxp3 reporter mice (Wan and
Flavell, 2005), IL-17A eGFP reporter mice (unpublished data), and IL-10
eGFP mice (Kamanaka et al., 2006) were crossed with dominant-negative
IL-10Ra mice (Cd4-DNIL-10R [Kamanaka et al., 2011]). Foxp3-cre-YFP-
Il10flox/flox mice were provided by Y.A. Rudensky (Rubtsov et al., 2008). Age-
and sex-matched littermates between 6 and 12 weeks of age were used. All
animal procedures were approved by the Institutional Animal Care and Use
Committee of Yale University.
Flow Cytometry
Anti-CD4, anti-CD62L, anti-CD44, anti-CD45.1, anti-CD45.2, anti-TCR-b, anti-
IFN-g, anti-IL-17A, anti-TNF-a, anti-IL-4, and anti-BrdU were purchased from
BD Bioscience.Immunity 34, 554–565, April 22, 2011 ª2011 Elsevier Inc. 563
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(Sigma, 50 ng/mL) and ionomycin (Sigma, 1 mM) for 4 hr. Golgistop (BD
Bioscience) was added during the last 3 hr of restimulation. After staining for
the extracellular markers, cells were fixated, permeabilized, and stained intra-
cellular for specific cytokines and GFP-FITC antibody (Invitrogen) to detect
IL-10 and IL-17A eGFP. Cells were acquired on a LSRII flow cytometer (BD)
and data analyzed with FlowJo software (Treestar) or FCS express.
For purification of T cell substes, CD4+ T cells were first enriched by
magnetic-activated cell sorting beads (MACS;Miltenyi Biotec) and then further
purified with a FACSVantage (BD). Purity of sorted cells was higher than 97%.
In Vivo T Cell Stimulation and Intestinal Lymphocyte Isolation
Mice were injected with anti-CD3 (15 mg, 145-2C11), isotype antibody, or PBS
i.p. two times every other day. After removal of the Peyer’s Patches, intraepi-
thelial lymphocytes (IEL) and lamina propria lymphocytes (LPL) were isolated
via incubation with 5 mM EDTA at 37C for 30 min (for IEL), followed by further
digestion with collagenase IV and DNase at 37C for 1 hr (for LPL). Cells were
then further separated with a Percoll gradient. If not indicated differently, cells
were isolated from the upper part of the small intestine (duodenum + jejunum)
of anti-CD3-treated mice.
Endoscopic Procedure
Colonoscopy was performed in a blinded fashion for colitis scoring via the
Coloview system (Karl Storz, Germany) (Becker et al., 2006). In brief, colitis
scoring was based on granularity of mucosal surface, stool consistence,
vascular pattern, translucency of the colon, and fibrin visible (0–3 points for
each).
Histopathology Procedure
Colons and small intestines were fixed in Bouin’s fixative solution and
embedded in paraffin. Colons were assigned scores by investigators blinded
to experimental manipulation. Each section was evaluated by a semiquantita-
tive criterion-based method (score 0–5) as described before (O’Connor et al.,
2009).
Cytokine Assays
Cytokines were quantified in the plasma via Cytometric Bead Array (BD Biosci-
ence) according to the manufacturer’s instructions.
Suppression Assays
CD45.1+CD4+CD25 T cells (responder cells) were labeled with CFSE (1 mM;
Invitrogen) and cultured in a 96-well round bottom plates (50 3 103 cells/well)
with or without FACS-sorted CD45.2+CD4+IL-10 eGFP+Foxp3 RFP (Tr1 cells)
isolated from the proximal part of the small intestine (duodenum + jejunum)
of CD3 antibody-treated mice. Irradiated APCs (splenocytes MACS depleted
for CD4+and CD8+ T cells) were used as feeder cells (400 3 103 cells/well).
Cells were stimulated with 2 mg/ml of CD3 antibody (2C11) in the presence
or absence of anti-TGF-b (1D11), anti-CTLA-4 (9H10), and anti-IL10Ra (1B1).
After 4 days, CFSE dilution in CD45.1+CD4+ (responder cells) was analyzed
by flow cytometry.
Statistical Analysis
The nonparametric Mann-Whitney U test was used to calculate statistical
significance via Prism. A p value of less than 0.05 was considered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and can be found with this
article online at doi:10.1016/j.immuni.2011.01.020.
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